Serological Response to HPV16 Infection

  • Anna Di Lonardo
  • M. Saveria Campo
  • M. Luisa Marcante


HPV infection of squamous epithelium of female genital. tract results in a variety of clinical. diseases. HPV types 6 and 11, are generally associated with benign proliferative lesions such as condylomata acuminata, while numerous “high risk” HPV types are involved in the development of cervical. dysplasia that can progress to malignancy. In particular HPV type 16 is one of the most important etiological. agent in cervical. squamous carcinoma. Several. studies have demonstrated that HPV16 infection can elicit a humoral. immune response. Serological. assays using different sources of HPV16 antigens, such as synthetic peptides, or protein expressed in prokaryotic or eukaryotic systems, have shown a significant correlation between the presence of antibodies to some HPV16 proteins and cervical. cancer. Antibodies against the transforming protein E6 and E7 have been detected frequently and with high seroprevalence in cervical. cancer cases1,2,3. In contrast little is known about the serological. response to the virus throughout the different stages of the infection to the development of the tumour.


Cervical Cancer Serological Response Gynaecological Clinic Cervical Biopsy Benign Proliferative Lesion 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    M. Muller, R.P. Viscidi, Y. Sun, E. Guerrero, P.M. Hill, F. Shah, F.X. Bosch, N. Munoz, L. Gissmann and K.V. Shah, Antibodies to HPV-16 E6 and E7 proteins as markers for HPV-16 associated invasive cervical. cancer, Virol. 187:508–514 (1992).CrossRefGoogle Scholar
  2. 2.
    A.K. Ghosh, N.K. Smith, S.N. Stacey, S.S.Glew, M.E. Connor, J.R. Arrand and P.L. Stern, Serological responses to HPV 16 in cervical. dysplasia and neoplasia: correlation of antibodies to E6 with cervical. cancer, Int J Cancer 53:591–596 (1993).PubMedCrossRefGoogle Scholar
  3. 3.
    S.N. Stacey, J.S. Bartholomew, A. Ghosh, P.L. Stern, M. Mackett and J.R. Arrand, Expression of human papillomavirus type 16 E6 protein by recombinant baculovirus and use for detection of anti-E6 antibodies in human sera, J Gen Virol. 73:2337–2345 (1992).PubMedCrossRefGoogle Scholar
  4. 4.
    J. Dillner, L. Dillner, G. Utter, C. Eklund, A. Rotola, S. Costa and D. Di Luca, Mapping of linear epitopes of human papillomavirus type 16: the L1 and L2 open reading frames, Int J Cancer 45:529–535 (1990).PubMedCrossRefGoogle Scholar
  5. 5.
    N. D. Christensen, J.W. Kreider, N.M. Cladel and D.A. Galloway, Immunological. cross-reactivity to laboratory produced HPV-11 virions of polysera raised against bacterially derived fusion proteins and synthetic peptides of HPV-6b and HPV-16 capsid proteins, Virol. 75:1–9 (1990).Google Scholar

Copyright information

© Springer Science+Business Media New York 1994

Authors and Affiliations

  • Anna Di Lonardo
    • 1
  • M. Saveria Campo
    • 2
  • M. Luisa Marcante
    • 1
  1. 1.Lab. of VirologyC.R.S. — Regina Elena Institute for Cancer ResearchRomeItaly
  2. 2.The Beatson Institute for Cancer Research — CRC Beatson LaboratoriesGlasgowUK

Personalised recommendations